Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 17/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 13/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579755 | 0.89 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9NPC1RAB9ACASP3 | |
| SCHEMBL3579073 | 0.89 | MAPKAPK2 (0.80) | MAPKAPK2MAPK9NPC1RAB9A | |
| SCHEMBL3584744 | 0.89 | MAPKAPK2 (0.83) | MAPKAPK2MAPK9NPC1RAB9ACDC7 | |
| SCHEMBL3581001 | 0.89 | MAPKAPK2 (0.80) | MAPKAPK2MAPK9CDC7 | |
| SCHEMBL3581621 | 0.86 | MAPKAPK2 (0.76) | MAPKAPK2MAPK9CDC7 | |
| SCHEMBL3586244 | 0.84 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9NPC1RAB9ACASP3 | |
| SCHEMBL3583943 | 0.83 | MAPKAPK2 (0.71) | MAPKAPK2MAPK9NPC1RAB9ACDC7 | |
| SCHEMBL3583940 | 0.83 | MAPKAPK2 (0.71) | MAPKAPK2MAPK9NPC1RAB9ACDC7 | |
| SCHEMBL3586366 | 0.82 | MAPKAPK2 (0.70) | MAPKAPK2MAPK9CDC7 | |
| SCHEMBL3994381 | 0.82 | MAPKAPK2 (0.69) | MAPKAPK2MAPK9CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | claimed |
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| WO-2008025512-A1 | PYRROLO ISOQUINOLINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069360-A1 | ORGANIC COMPOUNDS | SLCO1B3, CYP3A7, SLCO1B1 | MAPKAPK2 4563/4885MAPK9 2834/4885NPC1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.